Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,843 across all filing types
Latest filing 2017-03-14 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
独立董事的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion report for 普洛药业股份有限公司 regarding various corporate governance matters including profit distribution, related party transactions, internal control evaluation, guarantees for subsidiaries, appointment of auditors, and senior management appointments. It references compliance with Chinese securities regulations and company bylaws. The document is not a full annual report or financial statement but rather a governance-related opinion and compliance document issued by independent directors. It does not contain financial statements or earnings data, nor is it a brief announcement or a transcript. The content aligns with governance and board oversight information, specifically independent directors' opinions on corporate matters. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (3404 characters) and content support this classification with high confidence.
2017-03-14 Chinese
2016年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2016 年度内部控制评价报告' which translates to '2016 Annual Internal Control Evaluation Report'. It is a detailed report on the company's internal control evaluation for the fiscal year ending December 31, 2016. The content includes the board's statement, evaluation conclusions, scope of evaluation, internal control work basis, defect recognition and rectification, and other related matters. It is a comprehensive standalone report focused on internal control and audit-related matters rather than a full annual report or financial statement. The document length is 9127 characters, indicating it is a full report rather than a brief announcement. The nature of the content aligns with an Audit Report / Information filing, which covers audit reports, applied accounting principles, and internal control evaluations. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2016
2017-03-14 Chinese
2016年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as "普洛药业股份有限公司 2016 年年度报告摘要" which translates to "Pu Luo Pharmaceutical Co., Ltd. 2016 Annual Report Summary." It contains detailed financial data for the year 2016, including revenue, net profit, earnings per share, and asset information. It also discusses business operations, industry trends, shareholder information, and changes in consolidated entities. The length is 7,436 characters, which is substantial and contains actual financial data and analysis. The document is a summary of the full annual report, but it includes comprehensive financial and operational information typical of an annual report. Therefore, it should be classified as an Annual Report (10-K). FY 2016
2017-03-14 Chinese
2016年度独立董事述职报告（张爱珠）
Audit Report / Information Classification · 85% confidence The document is titled as an "Independent Director's Work Report for 2016" from a company's independent director. It details the director's attendance at board meetings, opinions on specific proposals, confirmation of quarterly and half-year reports, and supervisory activities during the year 2016. The content is a narrative report on the independent director's duties and activities rather than a full financial report or audit report. It does not contain financial statements or detailed financial data. It is not an announcement of voting results, nor a certification or regulatory filing. The document is a management-related report focusing on governance and oversight by an independent director, which aligns best with the category of Audit Report / Information (AR) because it includes the independent director's review and confirmation related to financial reports and governance compliance, but is not a full annual report or audit opinion itself. The document length is short (1719 characters), but it is a substantive report, not just an announcement. Therefore, the best fit is AR (Audit Report / Information). FY 2016
2017-03-14 Chinese
2016年度独立董事述职报告（张淼洪）
Board/Management Information Classification · 95% confidence The document is titled '2016 年度独立董事述职报告' which translates to '2016 Annual Independent Director's Work Report'. It details the independent director's attendance at board meetings, opinions on various company matters, and other supervisory activities during the year 2016. The content focuses on the independent director's duties, opinions on company governance, and compliance with regulatory requirements. It is not a full annual report, audit report, or financial statement, but rather a management or governance-related report by an independent director. This fits best under Board/Management Information (MANG) as it relates to board member activities and governance oversight. The document length is short (1583 characters), and it is a report itself, not an announcement of a report. Therefore, the classification is MANG with high confidence.
2017-03-14 Chinese
2016年监事会工作报告
Management Reports Classification · 95% confidence The document is titled as a '2016 年监事会工作报告' which translates to '2016 Supervisory Board Work Report' for 普洛药业股份有限公司. It details the supervisory board's activities, meetings, oversight of company operations, financial review, internal controls, and plans for 2017. It references the review of financial reports and audit reports but does not itself contain full financial statements or detailed financial data. The document is a report on the supervisory board's work and oversight rather than a full annual report or audit report. It is not an announcement or a brief notice but a substantive report on supervisory activities. Therefore, it fits best under the category of Management Reports (MDA), which includes management's detailed explanation of business trends, oversight, and outlook, rather than a full Annual Report (10-K) or Audit Report (AR). The document length (2344 characters) is sufficient for a detailed report but not a full financial report. Hence, the classification is MDA with high confidence.
2017-03-14 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.